Christopher Simon is the President and CEO of Haemonetics Corporation, a role he stepped into in May 2016. Before coming to Haemonetics, he worked for over 20 years at McKinsey & Company, where he specialized in global medical products. Notably,...
Christopher Simon is the President and CEO of Haemonetics Corporation, a role he stepped into in May 2016. Before coming to Haemonetics, he worked for over 20 years at McKinsey & Company, where he specialized in global medical products. Notably, Simon was deeply involved in the company's recent strategic review and helped shape their turnaround plan. Under his leadership, Haemonetics has seen impressive financial performance, achieving over $1 billion in revenue for the first time in its history in fiscal 2023. His compensation reflects his performance-oriented approach, with a reported total of $10.6 million in 2023, which included a significant annual bonus of $2.2 million based on the company's strong results. He also has a vested interest in the company’s success, owning approximately 109,940 shares of stock. Simon's pragmatic management style drives Haemonetics to maintain strong operational efficiency, especially during challenging market conditions. His mission is clear: to improve healthcare through innovative medical solutions and solidify Haemonetics' position in the market. As he continues to navigate the company through its strategic goals, Simon aims for sustainable growth and long-term value for shareholders.